"description","instanceType","name","uuid:ID","rationale","label","id"
"The main design for the study","StudyDesign","Study Design 1","6840e827-85d8-4f56-9d96-168f6010dbfe","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","StudyDesign_1"
